Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketograce Reno (also known as KETO&GRACE RENO) is an oral nutritional supplement developed by Biokindle Lifesciences specifically for patients with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). It is formulated as an albumen protein supplement containing approximately 79.51% albumen powder along with a mixture of 31 vital nutrients, including amino acids, vitamins, minerals, docosahexaenoic acid (DHA), and lycopene. The supplement is designed for patients undergoing dialysis or those on the verge of a kidney transplant to fulfill nutritional demands caused by low protein intake and to combat protein energy wasting (PEW). Once ingested, the albumen protein is converted to albumin in the liver, supporting the maintenance of serum albumin levels and overall nutritional status in renal patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ketograce Reno.